Welcome to our dedicated page for Staar Surg SEC filings (Ticker: STAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The STAAR Surgical Company (NASDAQ: STAA) SEC filings page on Stock Titan brings together the company’s official disclosures from the U.S. Securities and Exchange Commission. STAAR is a medical device manufacturer focused on ophthalmic surgery, and its filings provide detailed information on its implantable intraocular lens business, corporate actions, and governance.
Investors can review Current Reports on Form 8-K in which STAAR reports material events, such as the August 2025 Agreement and Plan of Merger with Alcon, subsequent amendments, the go-shop process, adjournments of special meetings of stockholders, and later communications about the failure to obtain shareholder approval and the intended termination of the merger agreement. Other 8-K filings describe litigation related to the merger proxy statement, preliminary and final financial results, and leadership changes, including the appointment of a Chief Financial Officer and the creation of a Capital Stewardship Committee of the Board.
Filings also confirm that STAAR’s common stock is listed on Nasdaq under the symbol STAA and document how the proposed merger, if completed, would have affected listing status and registration. By reading these documents, users can trace the evolution of STAAR’s strategic transaction with Alcon, the role of major shareholders in the process, and the company’s decision to remain a standalone, publicly traded entity after the merger was not approved.
On Stock Titan, STAAR’s SEC filings are updated as new documents are released on EDGAR. AI-powered tools summarize lengthy filings such as 8-Ks and related exhibits, helping users quickly identify key terms, conditions, and outcomes without reading every page. This makes it easier to track transaction terms, board and management changes, and other disclosures that shape the outlook for STAA within the ophthalmic medical device industry.
Broadwood Partners, Broadwood Capital and related individuals updated their ownership in STAAR Surgical Company’s common stock. Broadwood Partners and Broadwood Capital each report beneficial ownership of 16,123,842 shares, representing 32.6% of the 49,512,749 shares outstanding. Neal C. Bradsher may be deemed to beneficially own 16,149,742 shares, also 32.6%, through personal holdings and Broadwood Partners, while Richard T. LeBuhn reports 21,286 shares, or 0.0% of the class.
The amendment primarily reflects changes in beneficial ownership percentages and the fact that LeBuhn will cease to be a reporting person following this filing. The group continues to review its investment, may buy or sell shares over time, and remains in contact with management and other shareholders about ways to create additional shareholder value, but discloses no specific current plans for major corporate actions.
Broadwood Partners, L.P., a more-than-10% owner and director affiliate of STAAR Surgical, reported a series of open-market purchases of Common Stock. Between March 11 and March 13, Broadwood Partners bought a total of 670,213 shares at weighted average prices ranging from about $17.18 to $18.84 per share, with specific daily averages of
After these transactions, Broadwood Partners directly owned 16,123,842 shares of STAAR Surgical Common Stock. The filing notes that these securities are directly owned by Broadwood Partners and may be deemed indirectly beneficially owned by Broadwood Capital, Inc., as its general partner, and by Neal C. Bradsher, as President of Broadwood Capital. Each reporting person disclaims beneficial ownership beyond their economic interest. A separate holding entry shows 25,900 shares directly owned by Neal C. Bradsher.
STAAR Surgical director and 10% owner Neal C. Bradsher received an option grant to purchase 7,524 shares of common stock at an exercise price of $18.46 per share. The options expire on March 5, 2036 and are held directly.
The options will vest and become exercisable on the earlier of June 18, 2026 or the date of the company’s 2026 annual shareholder meeting, subject to his continuous service as a director. The grant was made on March 6, 2026 as director compensation under STAAR Surgical’s Amended and Restated Omnibus Equity Incentive Plan. Following this grant, Bradsher holds 7,524 options to purchase common stock.
STAAR Surgical director Richard T. LeBuhn received a grant of stock options as compensation. On March 6, 2026, he was awarded options to purchase 7,524 shares of common stock at an exercise price of
The options vest and become exercisable on the earlier of June 18, 2026 or the company’s 2026 annual meeting of shareholders, as long as he continues serving the company. The options expire on March 5, 2036, and following this grant he holds 7,524 options directly.
STAAR Surgical director Christopher Min Fang Wang received a grant of stock options covering 7,524 shares of common stock. The options have an exercise price of $18.46 per share and expire on March 5, 2036. They vest in full on the earlier of June 18, 2026 or the company’s 2026 annual shareholder meeting.
STAAR Surgical reported a difficult 2025, with full-year net sales of
Operating expenses in 2025 were
Management highlighted improved in-market demand and normalized inventories in China, strong early demand for the higher-priced EVO+ lens, and a manufacturing ramp in Switzerland designed to avoid US‑China tariff volatility. After shareholders rejected a proposed merger with Alcon in January 2026, STAAR appointed Warren Foust and Deborah Andrews as interim co‑CEOs and emphasized renewed focus on revenue growth, profit expansion and innovation as a standalone company.
STAAR Surgical Company reports a sharp downturn as its ICL-focused business faces macro and market headwinds. Net sales were $239.4 million for fiscal 2025, down 23.7% from 2024, and the company recorded a net loss of $80.4 million after a prior-year loss.
China remains critical, contributing about 32% of 2025 net sales, but weak consumer demand, elevated distributor inventories, and tariff concerns depressed volumes versus 2024. STAAR incurred $17.1 million of merger-related costs before stockholders voted down its proposed sale to Alcon and the merger agreement was terminated without any termination fee.
The company remains almost entirely concentrated in Implantable Collamer Lenses, having sold more than 4,000,000 ICLs worldwide and deriving approximately 100% of 2025 sales from these lenses. Finished goods inventory totaled $39.7 million, equal to 219 days’ inventory on hand, as STAAR builds buffers and dual manufacturing capacity in the U.S. and Switzerland.
STAAR ended 2025 with about 957 employees32.2%, well above medical device industry levels. Management highlights dependence on China, competitive pressure from laser vision correction and rival phakic lenses, and evolving regulatory regimes as key ongoing risks.
STAAR Surgical director Christopher Min Fang Wang filed an initial ownership report showing indirect beneficial ownership of 3,257,130 shares of common stock. The holdings consist of 2,575,061 shares owned by Yunqi Path Capital Master Fund and 682,069 shares owned by Yunqi China Special Investment A. Through his roles with the Yunqi entities, Mr. Wang may be deemed to beneficially own these shares, but he disclaims beneficial ownership except to the extent of his pecuniary interest.
STAAR Surgical Company reported that Chief Legal Officer and Corporate Secretary Nathaniel Sisitsky entered a letter agreement providing for his termination of employment, effective February 4, 2026, which will be treated as a termination by the company without cause.
Under the agreement, and consistent with his prior severance arrangement, he is eligible for 12 months of base salary and 12 months of reimbursed insurance premiums, subject to a general release. He will also receive his 2025 annual bonus on the same basis as executives who remain employed, plus a remaining cash recognition and retention award installment of $75,000.
STAAR Surgical also entered into a consulting agreement under which Sisitsky will provide legal transition services through March 13, 2026, or earlier if agreed, for fees of $8,000 per week and a potential $10,000 completion fee. Restricted stock units scheduled to vest in March 2026 vested as of his separation date, while all other unvested equity awards were forfeited.
STAAR Surgical granted restricted stock units to Interim Co-CEO and President & COO Warren Foust. On February 2, 2026, he received 20,787 RSUs, each representing one share of common stock upon vesting at a price of $0 per unit.
The RSUs will vest as to 100% of the shares on August 1, 2026, assuming the vesting conditions are met. Following this grant, Foust beneficially owns 20,787 derivative securities directly in the form of these RSUs.